The colorimetric determination of 1, 1-dimethylhydrazine (UDMH) in urine using trisodium pentacyanoamino ferroate (TPF) has heretofore been hampered by interfering substances in urine which resulted in poor recovery and some false negative results. A procedure was developed which overcame this difficulty and was primarily designed to determine rapidly in an emergency situation the urinary concentration of UDMH in exposed personnel. The procedure involves a hydrogen peroxide treatment of the urine followed by a colorimetric complexing of UDMH with TPF. In vivo results are presented on dogs that received intraperitoneal doses of UDMH with urinary concentrations of UDMH being determined in spontaneously voided and 24-hour pooled specimens.
INTRODUCTION
Large-scale use of 1, 1-dimethylhydrazine (UDMH) in the Titan II missile system has made the determination of this compound in air, water, blood, and urine samples highly desirable. Several methods have been described for the determination of various hydrazine derivatives (refs. [1] [2] [3] [4] [5] [7] [8] [9] , but none of these was specific for UDMH. The development of a screening procedure for urine was important since this laboratory has found that the urinary excretion of UDMH is an extremely sensitive and rapid indicator of exposure. In several preliminary experiments using animals that had received varying doses of UDMH, the ratio of the concentration per ml of urine to the concentration per ml of blood was approximately 20:1.
Experiments using monkeys (ref. 10) have indicated that pyridoxine hydrochloride in large doses (50 mg/kg*) is effective in preventing convulsions and death in animals receiving lethal doses of UDMH (100 mg/kg). Because of the discomfort associated with administration of such large therapeutic doses of pyridoxine (35 ml of a hypertonic solution for a 70-kg man), it would be advisable in an emergency situation to be guided by the urinary excretion level in the selection of cases which require treatment.
During the experimental phase of developing a procedure for analysis of urine, a factor inhibiting the formation of the color complex was observed in a large number of urines. Numerous attempts were made to eliminate the color-inhibiting substance(s). 6 ), the quality on each lot of this chemical must be checked by using the TPF evaluation technique described below. The TPF solution is stable for 8 hours at ordinary room temperature, but since TPF is a light-sensitive compound, the solution should be kept in a dark container.
In view of the difficulties with the Fisher reagent, sodium pentacyanoamino ferroate may be prepared in the laboratory:
Treat 10 grams of finely powdered (with mortar and pestle) sodium nitroprusside (Eastman Kodak -practical grade) in a flask with 32 ml of concentrated ammonium hydroxide overnight at refrigerator temperature.
Decant excess ammonium hydroxide and filter precipitate.
Wash the precipitate with absolute ethanol and anhydrous ether until dry.
The resulting sodium pentacyanoamino ferroate must be stored in a desiccator.
Buffer Solution: pH 5.4; 9.6 grams of citric acid (crystalline) and 15.7 grams of anhydrous disodium acid phosphate dissolved in 2 liters of distilled water.
Hydrogen Peroxide Solution: 0.3 percent; prepared from 3 percent H-Oa (USP) daily, using distilled water as the diluent. An accurate assay is required on long-standing solutions. A freshly opened bottle is preferable. Procedure Pipette 2 ml of urine to be tested into a cuvette.
Pool 5-ml aliquots of urine from 3 nonexposed persons, and pipette 2 ml of the pooled urine into another cuvette to serve as the blank.
Carefully pipette 0.02 ml of hydrogen peroxide into each cuvette. Wipe the outside of pipette before adding hydrogen peroxide and touch the drop to the inside of the tube just above the liquid level. Mix thoroughly by shaking.
AMRL-TDR-62-119
Add 13 ml of buffer to each cuvette. Add 1 ml of TPF reagent to each cuvette and mix.
Let the cuvettes stand for 20 minutes at room temperature to develop color.
Read the optical density of the unknown urine sample against the pooled negative urine blank set at 100 percent transmittance using 480 mg.
Read concentration from the standardization curve.
If the optical density of the unknown exceeds the range of the standardization curve, repeat the test using an appropriate dilution of the urine.
Standardization Curve
Obtain 5 urine samples from nonexposed persons.
Set up 16 cuvettes (3 for each urine sample and 1 for a blank).
Pipette 2 ml of urine into 3 cuvettes from each specimen. Mark the first cuvette 10 pg, the second cuvette 20 jug, and the third cuvette 30 ug per ml.
Pipette 2 ml of a pooled specimen (equal volumes) from the 5 samples into another. cuvette and mark it BLANK.
Add 0. 5, 1.0, and 1. 5 ml of the UDMH working standard solution to the respective cuvettes (all except the blank).
Carefully pipette 0.02 ml of hydrogen peroxide to each cuvette, including the blank. Wipe the outside of the pipette before delivering the H-0 2 and touch the drop to the inside of the cuvette just above the liquid level. Mix by shaking.
Add sufficient buffer to bring the total volume in each cuvette to 15 ml. Add 1 ml of TPF reagent to each cuvette and mix.
Read the optical densities of the calibration samples against the negative pooled urine blank set at 100 perCent transmittance using 480 mg.
Plot the mean values of the optical densities versus concentration of UDMH on linear graph paper for all 5 urines.
TPF Reagent Evaluation
This procedure is not part of the routine determination but must be used to determine the acceptability of each TPF lot. Pipette 2 ml of buffer into 3 cuvettes.
Add 0. 5, 1.0, and 1.5 ml of UDMH working standard solution to respective cuvettes.
Carefully pipette 0.02 ml of hydrogen peroxide solution to all cuvettes, observing the usual precautions. Mix by shaking.
Add sufficient buffer to bring the total volume to 15 ml.
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Prepare a blank using 15 ml of buffer. Add 1 ml of TPF reagent to all cuvettes. Mix.
Allow tubes to stand for 20 minutes.
Read the optical densities as previously described.
Construct calibration curve.
Refer to figure 1, calibration curve for TPF reagent.
If the angle of the slope of the constructed curve is substantially less than the curve in figure  1 , the lot of TPF is not suitable for this test. The importance of using H 2 0 2 is shown in figure 2 , which compares results of the analyses of 20 random human urine specimens using the standardization curve procedure described above, with and without H 2 02. The means and standard deviations of the optical densities for 10, 20, and 30 1g of UDMH per ml of urine, without H 2 02, were 0. 19 ± 0. 07, 0. 36 ± 0. 10, and 0. 53 + 0. 13. With H 2 02, the comparative optical density values were 0.22 ± 0.05, 0.43 ± 0.05, and 0.63 ± 0.07. Although the difference does not appear to be significant, the trend toward greater recovery is quite apparent. The means of the optical densities were increased at every level of concentration when H 2 0 2 was used. Table I illustrates this improvement much more clearly. Recovery in the individual urines that exhibited a high degree of inhibition without the addition of H 2 02 was significantly improved. Such improvement is particularly apparent in the results obtained on specimens 5 and 7.
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Recovery In Vivo
Five mongrel dogs were given water (30 mg/kg) by gastric intubation, and each was subjected to a single intraperitoneal injection of either 5, 10, 20, 30, or 40 mg/kg of UDMH. Following injection, they had access to water ad libitum. Urine samples were collected as they became available and analyzed for UDMH content using the method as described except for the addition of H 2 0e. The first few specimens were separately collected, and the final specimen was a pooled sample of all the urine subsequently produced by the animal within 24 hours. The results are listed in table II and indicate the relationship of dose to excretion level.
No valid correlation of dose with excretion level is possible from the results of such a limited number of animals. The data is presented merely to provide guidelines upon which to base an evaluation of human exposures. There appears to be a significant difference between urinary UDMH concentrations of the animal exposed to 10 mg/kg and of the one exposed to 40 mg/kg. Further, the relatively constant 24-hour excretion (as percentage of the total dose) in 3 out of 4 of the animals may well prove to be a valid figure when larger numbers of animals are used. The urine specimen from dog 3 that showed the least percent recovery in 24 hours (5. 7 percent) may have contained the inhibitory agent which could have caused the low values obtained. Since this work was performed prior to the development of the H 2 0 2 modification, we consider this explanation not only possible but probable. Recovery In Vitro
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Amounts of 10, 20, and 30 Mg of UDMH per ml of urine were added to 100 human urines and the optical densities were obtained as described under Standardization Curve. The results are shown in figure 3 . The means and standard deviations of optical densities for the above concentrations were, respectively: 0. 22 ± 0.05, 0.43 ± 0.07, and 0.64 ± 0.09. With UDMH in buffer solution (figure 1), the means and standard deviations of the optical densities for the same concentrations of UDMH were 0.26 ± 0. 02, 0. 50 + 0. 03, and 0. 74 + 0. 05. When compared with the recovery from buffer alone, the recovery of UDMH from buffered urine was 85 percent at the 10 Ag/ml concentration, and 86 and 87 percent at the 20 and 30 gg/ml levels, respectively. 
DISCUSSION
During the initial phase of this investigation, in vitro studies on the recovery of UDMH from human urine gave low erratic results due to the presence of a color-inhibiting substance(s) in urine which varied quantitatively from one specimen to another and appeared to be a commonly occurring constituent(s) of urine. Such unidentified color-inhibiting substance(s) presented the greatest problem in the development of a satisfactory and practical method. We observed no correlation between the extent of inhibition and the color of the urine. Complete inhibition of color was observed in some urine specimens even with the addition of 60 pg of UDMH per ml of urine. The potency of this factor was observed when as little as 0.4 ml of a severely inhibiting urine added to a 2-ml pooled urine specimen was capable of blocking color formation completely.
We attempted to adsorb both the UDMH and the color inhibitor from urine samples on activated Permutit columns, eluting only the UDMH with HC1. However, the tenacious adherence of UDMH to the column resulted in such poor recoveries that further efforts on a micro scale were considered impractical. Unsuccessful attempts were also made to extract the inhibitor with CCIh and CHC]3, both with and without HCI treatment. Using low concentrations of NaOC1 to selectively oxidize the inhibitor was tried and rejected.
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We achieved partial success in overcoming the inhibition by using a more concentrated TPF solution than previously cited (ref. 6). Using 1-202 further enhanced recovery of UDMH. The exact mechanism of action of I.0 on the inhibitor is not known at the present time. An irreversible reaction of .202 with the inhibitor-TPF complex appears to free the TPF for color formation with UDMH. * A soluble red color compound is formed with UDMH and TPF in urine, with an absorption optimum at 480 mu. We assumed that this red color is the result of the replacement of the NH. 3 
CIL LCEI
In approximately 250 UDMH-free urines no red color complex with TPF was observed during this test.
Chromogenic material, always present in urine, contributed to the somewhat large standard deviations in recovery studies. This variation was observed in an experiment in which the optical densities of 18 urines with added UDMH were corrected for their initial urine color. Since there is no need for great precision in a screening procedure, we felt that such correction was not essential.
In case of an extreme emergency involving significant exposure levels, an estimation of the final concentration of UDMH is possible almost immediately after the addition of TPF.
SUMMARY
A procedure for the determination of UDMH in urine was developed. The method includes treatment of urine with hydrogen peroxide and subsequent formation of a red TPF-UDMH complex. We attained 86 percent recovery for microgram quantities of UDMH in urine. There were no false negative results in over 100 urine specimens to which 10, 20, and 30 ug of UDMH per ml of urine were added. No false positive reactions were encountered. The procedure provides for rapid and convenient emergency determinations of significant UDMH concentrations in urine so that administration of effective therapy may be initiated before the onset of symptoms. 
